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Adult patients with primary immune thrombocytopenia requiring first-line treatment typically receive
corticosteroids, which are associated with low response rates and many potential side effects. In a
retrospective analysis of two 6-month, placebo-controlled, phase III trials, corticosteroid use decreased from
30 to 26% among patients treated with the novel thrombopoietin-mimetic romiplostim (n583) and remained
above 30% for placebo-treated patients (n542). Moreover, compared to placebo, patients were spared
7 weeks of corticosteroid treatment for every 100 weeks of romiplostim treatment. Thereafter, corticosteroid
use continued to decrease significantly, from 35 to 20%, in patients treated with romiplostim for up to 3 years
in an open-label extension study (n5101), and patients were spared a further 8 weeks of corticosteroid
treatment for each additional 100 weeks of romiplostim treatment. Such reductions in corticosteroids may
improve health-related quality of life in patients with primary immune thrombocytopenia.
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Introduction
Primary immune thrombocytopenia (ITP) is an auto-
immune disorder characterized by isolated thrombo-
cytopenia, with platelet counts below 100610
9/l.
1 In
adults, ITP typically has an insidious onset and a
chronic course.
ITP was historically thought to be a disease of
increased antibody-mediated platelet destruction.
Hence, traditional treatments have mainly targeted
the immune system, with oral corticosteroids given as
ﬁrst-line treatment.
2
While initial response rates with corticosteroids
range from 60 to 80%, durable response rates are only
10 to 25%.
3,4 Moreover, long-term corticosteroid use
can be associated with many side effects, including
cushingoid syndrome, mood and behavioural altera-
tions, infections due to immune suppression, dia-
betes, hypertension and musculoskeletal problems,
5
which can negatively impact health-related quality of
life (HRQOL).
6 Hence alternative, corticosteroid-
sparing, therapies are needed.
In recent years, evidence that impaired platelet
production also plays a role in ITP has emerged, and
new treatment strategies that stimulate platelet
production via the thrombopoietin (TPO)-receptor
have been developed.
7,8 Romiplostim was the ﬁrst
TPO-mimetic to be widely approved for the treat-
ment of chronic ITP in adults, and is recommended
for second- and third-line treatment of these
patients.
2 To date, continuous, long-term romiplos-
tim treatment has been shown to maintain platelet
counts for up to 5 years with minimal side effects.
9,10
Previous data have shown patients who received
romiplostim in two parallel, identically designed, 6-
month, placebo-controlled, phase III studies were
able to reduce or discontinue concurrent ITP
therapies, including baseline corticosteroids.
11,12 The
analysis presented here further describes the reduced
corticosteroid use observed during these studies, and
demonstrates that corticosteroid use remains low
among patients treated with romiplostim for up to
3 years during an open-label extension study.
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The studies included in this analysis have been
reported elsewhere.
9,11 The study protocols were
approved by the relevant institutional review boards.
Patients could enter the studies while receiving
concurrent ITP therapies at a constant dose and
schedule. Dose reductions were permitted during the
ﬁrst 12 weeks of the phase III studies, if platelet
counts were above 100610
9/l. In the extension study,
concurrent therapies could be reduced or discontin-
ued after a platelet count >50610
9/l was achieved.
Dose increases and the use of rescue therapies were
permitted at any time during the phase III studies and
when platelet counts fell below 10610
9/l in the
e x t e n s i o ns t u d y .T a r g e tp l a t e l e tc o u n tw a s5 0 –
200610
9/l in the phase III studies and 50–250610
9/
l in the extension study.
As reported elsewhere, the demographics and
baseline characteristics of patients enrolled in the
phase III studies were similar;
11 hence data from
these studies were pooled for the analyses described
here. Incidence of corticosteroid use in each 4-week
study period was plotted by treatment group, and
mean daily dose plotted for patients continuing to
receive prednisone-type corticosteroids. For each
treatment group, average duration of exposure to
corticosteroids per 100 subject-weeks of exposure to
study drug was also calculated.
The analyses described for the extension study
include interim data from patients previously enrolled
in the phase III studies, collected as of July 2008.
Efﬁcacy and safety results from this interim data have
been reported elsewhere.
13 Incidence of corticosteroid
use was plotted for each 24-week period in which at
least ﬁve patients remained on study. The reduction
in corticosteroid use over time was tested for
statistical signiﬁcance using a logistic regression
model, using corticosteroid use as a binary response
variable, time as a main effect and a random
intercept. Mean daily dose was plotted for patients
continuing to receive prednisone-type corticosteroids.
Average duration of exposure to corticosteroids per
100 subject-weeks of exposure to romiplostim was
also calculated.
Results
In total, 125 subjects (83 romiplostim, 42 placebo)
were randomized into the phase III studies; 102 of
whom subsequently entered the extension study
(Fig. 1). At the time of this analysis, patients from
the phase III studies had been treated in the extension
study for up to 144 weeks (median exposure to
romiplostim 102 weeks).
Patients receiving romiplostim and placebo in the
phase III studies had similar demographics and
baseline characteristics.
11 Overall, median age was
52 years (range 21–88 years), mean platelet count
was 16610
9/l (range 2–31610
9/l), 65% (81/125)
patients were female, 50% (63/125) were splenecto-
mized and 94% (118/125) had previously received
corticosteroids for ITP. At baseline, use of concur-
rent ITP medications was lower in the romiplostim
group (23/83 [28%] vs 16/42 [38%]).
During the phase III studies, cumulative exposure
to study drug was 1891 and 774 weeks for romiplos-
tim- and placebo-treated patients, respectively. Cu-
mulative exposure to corticosteroids was 443 and
236 weeks, respectively. Hence, for every 100 weeks
of exposure to romiplostim and placebo, patients
received corticosteroids for an average of 23.4 and
30.5 weeks.
Inthephase IIIstudies,therate ofcorticosteroiduse
among romiplostim-treated patients decreased from
30% during weeks 1–4 to 26% during weeks 21–24.
Corticosteroid use among placebo-treated patients
remained above 30% (Fig. 2A). In both treatment
groups, the majority of patients requiring corticoster-
oids received prednisone-type steroids (romiplostim:
28/31 [90%], placebo: 17/19 [89%]). Among romiplos-
tim-treated patients, mean daily prednisone dose
decreased from 20 to 7 mg by week 19, before
increasing slightly to 13 mg by week 24. Mean daily
dose also decreased in placebo-treated patients
(Fig. 2B).
During the extension study, cumulative exposure
to romiplostim and corticosteroids was 9437 and
1417 weeks, respectively. Hence, for every 100 weeks
of exposure to romiplostim, patients received corti-
costeroids for an average of 15.0 weeks.
Corticosteroid use continued to decrease during
the extension study (Fig. 2C). During weeks 1–24,
35% of patients received corticosteroids, compared
with 20% during weeks 121–144. A logistic regression
Figure 1 Subject disposition (July 2008). *Reasons for
discontinuation from the phase III studies have been
reported elsewhere
11; {1 subject withdrew consent prior to
receiving romiplostim.
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signiﬁcant (P50.0003), and estimated that the odds
of receiving corticosteroids decreased by 13% for
every 24 weeks of romiplostim treatment received.
The majority of patients requiring corticosteroids
received prednisone-type steroids (31/39 [79%]).
Mean daily prednisone dose decreased from 15 to
5 mg after 1 year of romiplostim treatment.
Discussion
Corticosteroids, the conventional ﬁrst-line treatment
in adult patients with ITP, have limited, short-term
efﬁcacy, and are associated with many side effects
which can have a detrimental effect on HRQOL.
Hence alternative, corticosteroid-sparing, therapies
are needed.
Romiplostim is a novel, TPO-mimetic which is
approved for the treatment of chronic ITP in adults.
To date, continuous long-term treatment has been
shown to maintain platelet counts for up to 5 years
with minimal side effects.
9,10 In the retrospective
analysis presented here, concomitant corticosteroid
use among patients treated with romiplostim for up
to 3 years was analyzed.
In two placebo-controlled, phase III studies, the
rate of corticosteroid decreased from 30 to 26%
among romiplostim-treated patients, and remained
above 30% in placebo-treated patients. While the
analyses presented had insufﬁcient power to demon-
strate statistical signiﬁcance, the differences observed
are deemed clinically relevant. Indeed, patients were
spared 7 weeks of corticosteroid treatment for every
100 weeks of romiplostim treatment. In an open-label
extension study, corticosteroid use continued to de-
crease. After 3 years of continuous romiplostim treat-
ment, the rate of corticosteroid use had decreased
from 35 to 20%, a reduction that was statistically
signiﬁcant. Moreover, patients were spared an addi-
tional 8 weeks of corticosteroid treatment for each
additional 100 weeks of romiplostim treatment.
While some patients continued to receive corticos-
teroids, the dose administered in these patients
decreased. This trend was observed for both romi-
plostim- and placebo-treated patients. The decrease
in the placebo group may be due to the widespread
use of rescue medications among these patients,
which has been reported elsewhere.
11,14 Further-
more, in the phase III studies corticosteroids were
reduced when platelet counts were below 100610
9/l,
a higher threshold than used in clinical practice.
Hence, the corticosteroid-sparing effect of romiplos-
tim may be underestimated in this analysis.
Conclusion
The analyses presented demonstrate that concomi-
tant corticosteroid use is reduced among patients
treated with romiplostim, and remains low during
long-term treatment with this agent. In addition, data
in patients treated for up to 5 years show that
continuous, long-term, romiplostim treatment safely
and effectively maintains platelet counts.
9,10 Hence
romiplostim is an important corticosteroid-sparing
Figure 2 (A) Corticosteroid use decreased in romiplostim-
treated patients during two, 6-month, phase III studies.
Percentages calculated from n5number of subjects remain-
ing on study at the start of the relevant time period.
(B) Prednisone dose decreased in patients continuing to
receive corticosteroids during the phase III studies.
N5Number of subjects receiving prednisone-type corticos-
teroids during the phase III studies; n5number of subjects
receiving prednisone-type corticosteroids at specified time
point. (C) Corticosteroid use decreased significantly over
time in patients treated with romiplostim for up to 3 years in
an open-label extension study. n5number of subjects
remaining on study.
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alleviating the side effects associated with corticoster-
oids. This improvement in HRQOL needs to be
quantiﬁed in controlled, prospective studies.
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